RU2598338C1 - Method for the treatment of serous mastitis in cattle - Google Patents

Abstract

FIELD: veterinary science.

SUBSTANCE: invention relates to veterinary medicine and is intended for treatment of mastitis in cattle. Method includes the intracisternal administration of the antibacterial preparation in a dose of 15 ml per one animal 1-2 times a day for 3-4 days.

EFFECT: use of the claimed method is highly effective for the treatment of serous mastitis in cattle.

1 cl, 4 tbl, 3 ex

Description

The invention relates to the field of veterinary medicine, in particular, can be used in the treatment of serous mastitis in cattle.

Mastitis is one of the common diseases of cows. This is due to the fact that the mammary gland is one of the most intensively functioning organ and, under mechanized milking of cows, undergoes often external inadequate physiology of the animal. Primary irritation of the udder under inappropriate animal health conditions (low temperature, high humidity and bacterial contamination of the premises). Depending on the degree of exposure to pathogenic factors and the state of resistance of the body of cows, the process in the udder can lead to subclinical, and then clinical forms of the disease (serous, etc.). Subclinical mastitis is characterized by a sluggish inflammatory process, in which the clinical signs of mastitis are very poorly expressed, or even do not appear. With the serous form of mastitis, the inflammatory process is more difficult, since there is a lesion of the vast area of the udder parenchyma (V. I. Slobodyanik. Immunological aspects of solving the mastitis problem. - Veterinary of farm animals. - 2010. - No. 10. - P. 20-27).

Known methods of treating mastitis in cows using drugs: mastilex, mastisan, masticide (Shabunin S.V., Klimov N.T., Nezhdanov A.G. Actual problems of therapy and prevention of mastitis in cows // Veterinary medicine. - 2011. - No. 12 . - S. 3). As active substances in these preparations, combinations of antibiotics, sulfonamides stabilized in an oil base are used. The therapeutic dose of drugs is 10 ml and contains cephalexin monohydrate 350 mg, gentamicin sulfate 25 mg, excipient d.c. up to 10 ml; potassium salts of benzylpenicillin 100000 U, streptomycin sulfate 100000 U, norsulfazole soluble 0.35 g, oil base 4.5 g, emulsifier 0.05 g. The drugs are administered intracisternally in the milk channel at a dose of 10 ml twice a day with an interval of 12-24 hours within 3-4 days.

The disadvantages of this method of treating cows with mastitis with antibiotics are rejection of milk after treatment, the spontaneous selection of antibiotic-resistant strains of microorganisms, a decrease in milk productivity due to dystrophy of the udder tissue as a result of mastitis. The action of the drugs is based on the destruction of the wall of the microorganism or the inhibition of protein-synthesizing processes in the DNA and RNA cell of the causative agent of infectious mastitis.

The closest solution adopted for the prototype is the drug for the treatment of cows with subclinical mastitis and the method of its application (application for the grant of a patent of the Russian Federation No. 2532407 dated 10.11.2014) by intracisternal administration of the drug, as active substances containing silver nanoparticles stabilized by submicron particles of dioxide titanium, poly-N-vinylpyrrolidone-2, water obtained by electrochemical method. The drug is injected into the milk channel at a dose of 10 ml twice a day with an interval of 12 hours for 2-4 days.

The disadvantages of the prototype method are: the high cost of the drug associated with the method of its manufacture, low therapeutic efficacy due to the long duration of treatment, is not used to treat serous mastitis in cows.

The problem solved by the claimed invention is to expand the arsenal of tools and method of application.

The problem is solved in that in the method for the treatment of serous mastitis in cattle, including intracisternal administration of an antibacterial drug, according to the invention, the drug Argovit is used as an antibacterial drug in a dose of 15 ml per 1 animal 1-2 times a day for 3-4 days.

The invention is illustrated by the following examples.

Argovit is a complex of highly dispersed particles of cluster silver, polyvinylpyrrolidone and an aqueous solution obtained by the electro-radiation method. The drug has a wide spectrum of antimicrobial activity against gram-positive and gram-negative, aerobic and anaerobic, spore-forming and asporogenic bacteria in the form of monocultures and microbial associations. Manufacturer LLC SPC "Vector Vita", e-mail: vectot-vita@ngs.ru.

This drug was previously used to treat calf colibacillosis (application for the grant of a patent of the Russian Federation No. 2147237 dated 01/14/1999), for external treatment of purulent wounds (TU 9310-13-0000-8064), (Shcherbakov S.A. et al. Experience with Ag -containing preparations Argogel and Argovit in the treatment of purulent wounds // News “Vector Best.” - 2001. - No. 2 (20). Ufimtsev V.A. et al. Experience of using Ag-containing preparations Argogel and Argovit for local treatment of purulent wounds // News “Vector Best.” - 2001. - No. 2 (20). - S. 78-81).

Due to the fact that the drug was not previously used, it was necessary to conduct studies of the irritating effect of the drug, including a complex of highly dispersed particles of cluster silver, polyvinylpyrrolidone and an aqueous solution, on the mammary gland of cows for the treatment of serous mastitis in cows.

Example 1

Studies of the irritating effect of the drug, including a complex of highly dispersed particles of cluster silver, polyvinylpyrrolidone and an aqueous solution, on the mammary gland of cows have been carried out.

Fifteen clinically healthy cows of black-motley breed were selected according to the principle of analogues. The drug was administered intracisternally in the left lobes of the udder at a dose of 15 ml per 1 animal, the right lobes served as a control. After administration of the drug Argovit at 6, 12, 24, 48 and 72 hours, the state of the udder was taken into account, as well as milk samples were taken to calculate the number of somatic cells. In the study of milk samples for the content of somatic cells, their insignificant increase (by 12.2%) was noted 6 hours after drug administration, and 48 hours after drug administration, the number of somatic cells decreased to 346.3 ± 16.1 thousand / ml was within the physiological norm (table. 1).

Thus, the drug does not irritate the mammary gland of cows and can be recommended for intracisternal administration.

Example 2

To determine the most optimal therapeutic dose of a preparation containing highly dispersed particles of cluster silver obtained by the electroradiative method, three groups of black-motley cows of the second and fourth lactation patients with serous mastitis were formed by the principle of analogues. The animals were injected intracisternally Argovit, 15 ml per animal 1-2 times a day with an active substance concentration of 15 ml / l.

The use of the drug with an active substance concentration of 15 ml / l in a dose of 5-10 ml showed the least therapeutic effect in the treatment of serous mastitis in cows. Recovery on average occurred on 4.1-4.6 days.

The use of the drug with an active substance concentration of 15 ml / l at a dose of 15 ml per 1 animal showed the greatest therapeutic effect in the treatment of serous mastitis in cows, while recovery took place on 3.3 days. The use of the drug with an active substance concentration of 15 ml / l in a dose of 20 ml per 1 animal is characterized by similar indicators of recovery time, as the use of the drug in a dose of 10 ml (Table 2).

From the generalized results it follows that the greatest therapeutic effect in the treatment of serous mastitis in cows was achieved with the use of the drug in group 3 (15 ml). However, the use of the drug in a dose of 20 ml did not reveal a significant increase in therapeutic effectiveness and led to an overexposure of the active substances that make up the drug.

The research results showed that the most effective dose of the drug, which has a pronounced therapeutic effect and a shorter treatment period (3.3 ± 0.2 days), is a dose of 15 ml.

Example 3. Determination of therapeutic efficacy of an antibacterial drug with an active substance concentration of 15 ml / l in the treatment of bovine serous mastitis

To study the comparative effectiveness of cows serous mastitis therapy according to the analogue principle, three groups of animals were formed: the first group (n = 22) was injected with Mastiton Forte (contains: 200 mg oxytetracycline, 250 mg neomycin, 2000 ME bacitracin, 10 mg prednisolone) intracisternally 10 ml, 1 time per day; the second group (n = 22) was administered a drug containing silver nanoparticles stabilized by submicron particles of titanium dioxide, poly-N-vinylpyrrolidone-2, water obtained by the electrochemical method (Argomast) intracisternally at a dose of 15 ml, 2 times a day for 2- 4 days; the third group was injected intracisternally with an antibacterial drug containing a complex of highly dispersed particles of cluster silver (Argovit) with a concentration of the active substance of 15 ml / l in a dose of 15 ml per animal 1-2 times a day until recovery.

The therapeutic efficacy of Argovit was determined by the number of days of treatment, the duration of which was determined by a negative dimastin test. Somatic cells were also counted daily in the Goryaev's counting chamber, where the rate of recovery was their presence in an amount of less than 400 thousand cells / per 1 ml of milk. By the time of recovery, the local temperature of the mammary glands treated was within the physiological norm, the skin of the udder was elastic and painless (Table 3).

During treatment, in samples of the secretion of the udder from the cows of the experimental and control groups, a decrease in the content of somatic cells with serous mastitis was noted - by 61.5; 60.5 and 70.1%, respectively.

The average duration of treatment of serous mastitis in cows of the control group with Mastiton Forte was 6.6 ± 0.1 days. At the same time, milk from these cows was disposed of within four days, according to the instructions for use of the drug (table. 4).

Thus, the total term for milk culling from control cows (Mastiton Forte) for patients with serous mastitis was 10.6 days, while during the treatment of the same mastitis with Argomast, the average treatment period was 5.7 days, and Argovit 3.3 days, respectively .

Thus, the proposed method for the treatment of serous cattle using an antibacterial preparation containing highly dispersed particles of cluster silver with an active substance concentration of 15 ml / l, with an intracisternal route of administration at a dose of 15 ml per 1 animal, 1-2 times a day, is more acceptable in comparison with other methods of treatment (Mastiton Forte and Argomast), which was expressed in a decrease in the duration of therapy and a decrease in somatic cells in milk.

In this regard, our proposed method for the treatment of serous mastitis in cattle using an antibacterial preparation containing highly dispersed particles of cluster silver with a concentration of the active substance of 15 ml / l, at a dose of 15 ml per 1 animal 1-2 times a day contributes to the improvement of therapeutic measures, accompanied by a reduction in the treatment of mastitis in cows by 1.7-2 times.

Claims (1)

1. A method for the treatment of serous mastitis in cattle, including intracisternal administration of an antibacterial drug, characterized in that the drug Argovit is used as an antibacterial drug in a dose of 15 ml per animal 1-2 times a day for 3-4 days.